Fibrinolytic Therapy Market
According to Intent Market Research, the Fibrinolytic Therapy Market is expected to grow from USD 2.0 billion in 2023 at a CAGR of 8.7% to touch USD 3.6 billion by 2030. The Fibrinolytic Therapy Market is dominated by key players such as AbbVie Inc., Amgen Inc., Bayer AG, Boehringer Ingelheim, CSL Behring, Genentech, Inc. (Roche Group), Johnson & Johnson, LFB Group, Mylan N.V., Novartis AG, Pfizer Inc., Sanofi and Teva Pharmaceuticals Industries Ltd.